Nursing home residents at heightened risk of falling in the days followingJuly 18, 2011
Increased surveillance over 48-hour period may decrease falls
BOSTON-Nursing home residents taking certain antidepressant medications are at an increased risk of falling in the days following the start of a new prescription or a dose increase of their current drug, according to a new study by the Institute for Aging Research of Hebrew SeniorLife, an affiliate of Harvard Medical School.
Published online in the Journal of Gerontology: Medical Sciences, the study found that nursing home residents have a fivefold increased risk of falling within two days of a new prescription for or an increased dose of a non-SSRI (selective serotonin reuptake inhibitor) antidepressant such as bupropion or venlafaxine. The findings suggest that nursing home staff should closely monitor these residents following a prescription change to prevent potential falls.
"Our results," says lead author Sarah D. Berry, M.D., M.P.H., a scientist at the Institute for Aging Research, "identify the days following a new prescription or increased dose of a non-SSRI antidepressant as a window of time associated with a particularly high risk of falling among nursing home residents."
The risk of falls, she says, may be due to acute cognitive or motor effects that have not yet been fully investigated. Certain non-SSRIs, such as trazodone, can cause postural hypotension, a dramatic decrease in blood pressure upon standing that may contribute to falls. Other non-SSRIs, like venlafaxine, can cause sedation and coordination problems that may lead to falls.
According to some estimates, more than one-third of the country's nearly 1.6 million nursing home residents take some type of antidepressant medication. Several previous studies have implicated antidepressants, including both SSRIs, such as paroxetine and sertraline, and non-SSRIs, as a risk factor for falls, especially among older adults; however, it is unclear if the risk accrues during the duration of use or if there are acute risks associated with the initiation or change in dose of a prescription.
Both tricyclic antidepressants and SSRIs, the most commonly prescribed antidepressant medications, have been associated with up to a sixfold increased risk of falls among nursing home residents in other studies. Newer drugs, including serotonin-norepinephrine reuptake inhibitors, may also be associated with falls risk. Regardless, says Dr. Berry, "these drugs are effective at treating the symptoms of depression, and many clinicians are reluctant to withhold their use based solely on a risk for falls."
Although many studies have examined chronic antidepressant use as a risk factor for falls, few have considered the short-term effects of a change in antidepressant prescription. Dr. Berry's study, called a case-crossover study, examined 1,181 residents of a Boston-area nursing home who fell, comparing the frequency of antidepressant changes during a "hazard" period (1-7 days before a fall) with the frequency of antidepressant changes during a control period (8-14 days before a fall). Information on falls was collected using the facility's federally-mandated computerized incident reports. The risk of falls was greatest within a two-day period of a change in a non-SSRI prescription (either new or existing), while no association was found between SSRIs and falls. The risk of falls diminished each day following the prescription change.
In light of her findings, says Dr. Berry, an instructor in medicine at Harvard Medical School, "nursing home staff should keep a watchful eye on residents in the days following a non-SSRI antidepressant change to prevent falls and clinicians should avoid making changes on weekends or during times when unfamiliar staff is present."
The study was funded by a grant from the National Institute on Aging, the Hartford Geriatrics Health Outcomes Research Scholars Awards Program, and the Men's Associates of Hebrew SeniorLife.
Scientists at the Institute for Aging Research seek to transform the human experience of aging by conducting research that will ensure a life of health, dignity and productivity into advanced age. The Institute carries out rigorous studies that discover the mechanisms of age-related disease and disability; lead to the prevention, treatment and cure of disease; advance the standard of care for older people; and inform public decision-making.
Founded in 1903, Hebrew SeniorLife, an affiliate of Harvard Medical School, is a nonprofit, nonsectarian organization devoted to innovative research, health care, education and housing that improves the lives of seniors. For more information, please visit www.hebrewseniorlife.org.
Hebrew SeniorLife Institute for Aging Research
Related Antidepressant Current Events and Antidepressant News Articles
VUMC study may offer answers for treating depression in alcoholics
A study by researchers at Vanderbilt University Medical Center is offering a glimmer of hope to alcoholics who find it hard to remain sober because their abstinence is hounded by stubborn, difficult-to-treat depression.
Antidepressants during pregnancy do not pose risk to unborn child
Women who take antidepressants during pregnancy do not appear to be at greater risk of giving birth to children with congenital heart defects compared to women who are not exposed to the drugs, according to new research from UCL.
Experts offer new approach to prioritizing research on the environmental impacts of pharmaceuticals
Researchers have developed a new way to prioritize investigations on the environmental impacts of the estimated 1500 active pharmaceutical ingredients currently in use.
Depression of either parent during pregnancy linked to premature birth
Depression in both expectant mothers and fathers increases the risk of premature birth, finds a study published in BJOG: an International Journal of Obstetrics and Gynaecology (BJOG).
Emotion-processing networks disrupted in sufferers of depression
Regions of the brain that normally work together to process emotion become decoupled in people who experience multiple episodes of depression, neuroscientists report. The findings may help identify which patients will benefit from longterm antidepressant treatment to prevent the recurrence of depressive episodes.
Study finds no increased risk of autism, ADHD with prenatal antidepressant exposure
An analysis of medical records data from three Massachusetts health care systems finds no evidence that prenatal exposure to antidepressants increases the risk for autism and related disorders or for attention-deficit hyperactivity disorder (ADHD).
Certain antidepressants linked to heightened risk of mania and bipolar disorder
Taking certain antidepressants for depression is linked to a heightened risk of subsequent mania and bipolar disorder, reveals research published in the online journal BMJ Open.
No treatment difference between some antidepressants and CBT for severe depression
The available evidence suggests no difference in treatment effects of second generation antidepressants and cognitive behavioral therapy (CBT) either alone or in combination, for patients with major depressive disorder, finds a study in The BMJ today.
Antidepressant with novel action appears safe and effective in phase 1b clinical trial
A small clinical trial of a novel antidepressant that stimulates neurogenesis - the production of new brain cells - shows that the compound appears to be safe and may be effective against depression.
Taking antidepressants with cancer drug does not increase breast-cancer recurrence
A large study of patients with breast cancer who took the anti-cancer drug tamoxifen while taking an antidepressant were not found to have an increased risk of recurrence. The Kaiser Permanente study was published today in The Journal of the National Cancer Institute.
More Antidepressant Current Events and Antidepressant News Articles